2025-04-08 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Report

**0) Summary Statistics:**

UNH, UnitedHealth Group Inc., is a diversified healthcare company.  The following analysis uses provided data to evaluate its performance.

**1) Performance Comparison & Divergence:**

* **UNH Cumulative Return:** 91.95%
* **VOO (S&P 500) Cumulative Return:** 73.15%
* **Return Difference:** 18.8%  This means UNH outperformed the S&P 500 by 18.8% over the period considered.
* **Relative Divergence:** 38.8% (This indicates UNH's outperformance is in the upper 38.8th percentile of its historical range of outperformance relative to the S&P 500, based on a minimum of -34% and maximum of 102%).

**Alpha and Beta Analysis:**

The provided data shows fluctuating alpha and beta values across different periods.  While alpha (excess return relative to the market) is generally positive, indicating outperformance, it's inconsistent. Beta (volatility relative to the market) is significantly above 1 in most periods, suggesting higher than average volatility.  Market capitalization (Cap(B)) has steadily increased over time.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 69.0% | 5.8% | 39.0% | 0.1 | 181.0 |
| 2016-2018  | 60.0% | 10.4% | 42.0% | 0.1 | 207.3 |
| 2017-2019  | 46.0% | 10.4% | 15.0% | 0.4 | 248.8 |
| 2018-2020  | 12.0% | 10.4% | -19.0% | 0.4 | 301.7 |
| 2019-2021  | 76.0% | 9.3% | 2.0% | 0.5 | 438.0 |
| 2020-2022  | 78.0% | 9.3% | 69.0% | 0.5 | 468.4 |
| 2021-2023  | 46.0% | 57.3% | 25.0% | 0.4 | 472.1 |
| 2022-2024  | -44.0% | 61.0% | -64.0% | 0.3 | 460.8 |
| 2023-2025  | -34.0% | 61.0% | -47.0% | 0.1 | 479.9 |


**2) Recent Price Movement:**

* **Closing Price:** $524.70
* **Previous Close:** $525.05
* **Change:** -$0.07 (a small decrease)
* **5-day Moving Average:** $527.30
* **20-day Moving Average:** $510.58
* **60-day Moving Average:** $510.89

The price is slightly below its 5-day moving average but above both its 20-day and 60-day moving averages, suggesting a recent slight downward trend.

**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4792 (High Risk according to provided ranges)
* **RSI:** 65.68 (Approaching overbought territory; values above 70 are typically considered overbought)
* **PPO:** 0.43 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +14.0 (Short-term upward trend)
* **Expected Return:** 74.6% (A significant expected return over the S&P 500 over the long term).

The combination of high MRI, RSI nearing overbought territory and recent slight price decrease suggests caution.  However, the positive PPO and substantial expected return signal potential for growth in a longer time frame.

**4) Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-11-04 | 6.56  | $100.82 B    |
| 2024-08-09 | 4.58  | $98.86 B    |
| 2024-05-09 | -1.53 | $99.80 B    |
| 2023-11-06 | 6.31  | $92.36 B    |
| 2024-11-04 | 6.31  | $92.36 B    |


There seems to be a duplicate entry for 2024-11-04. Revenue is consistently high, but EPS shows significant fluctuation.  The negative EPS in Q2 2024 is noteworthy and requires further investigation to understand the cause.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |
| 2024-03-31 | $99.80B    | 23.05%        |
| 2023-12-31 | $94.43B    | 23.30%        |

Revenue is relatively stable and high. Profit margins are healthy but show slight downward trend recently.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $92.66B    | 5.98%         |
| 2024-09-30 | $94.53B    | 6.41%         |
| 2024-06-30 | $89.36B    | 4.72%         |
| 2024-03-31 | $86.69B    | -1.63%        |
| 2023-12-31 | $88.76B    | 6.15%         |

Equity shows some fluctuation.  The negative ROE in Q1 2024 is concerning and requires further investigation.


**6) Overall Analysis:**

UNH has historically outperformed the S&P 500, exhibiting higher returns but also greater volatility.  Recent performance shows a slight decline, with the price slightly below its 5-day moving average.  While the expected long-term return is high, several factors warrant caution: high market risk, RSI approaching overbought levels, and inconsistent earnings with a notable negative EPS in Q2 2024.  Further investigation into the causes of the negative EPS and ROE in Q1 and Q2 2024 is crucial before making any investment decisions. The high beta suggests that UNH's returns are strongly correlated with market movements, increasing risk.  A long-term investment strategy might be appropriate for risk-tolerant investors, but thorough due diligence and monitoring are essential.
